Quick take: Bintai Kinden rises 6% on exclusive distributor appointment thestar.com.my - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestar.com.my Daily Mail and Mail on Sunday newspapers.
’s partner Generex Biotechnology Corporation has filed for a trademark for its li-Key vaccine and patent for its Ii-Key-SARS-CoV-2 vaccine.
In a statement issued on Thursday, Bintai Kinden said the Ii-Key vaccine was designed to be a complete vaccine for the Covid-19.
“The technology offers the safest and best route for the rapid development of a Covid-19 vaccine, ” it said.
It explained the complete vaccine is designed to regulate the immune system to provide a targeted, neutralising antibody response.
Bintai Kinden managing director Ong Choon Lui said Generex’s Covid-19 vaccine was based on the results of the ex-vivo human studies. It will be formulated for phases one and two clinical trials.
KUALA LUMPUR: Bintai Kinden Corp Bhd’s partner, Generex Biotechnology Corp has filed for a trademark for its li-Key vaccine, to be known as “The Compl.